Actualidad Menarini

Busca noticias de Menarini-CA

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

III Simposium Centroamericano y del Caribe de Neurociencias

Protección y reparación de los tejidos de la mucosa bucal, ácido hialurónico de origen biotecnológico

Simposium Panamericano de Medicina del Deporte

V Seminario de Medicina del Deporte y Rehabilitación

Módulo 4: I Master Course de Actualización en Odontoestomatología

«
1 de 25
«